Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAHRTS trial of higher thoracic radiotherapy dose with durvalumab in limited-stage small-cell lung cancer
NL-OMON61474Phase 3Not yet recruiting
- Sponsor
- NTNU
- Start
- Jul 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of durvalumab in small cell lung cancer (SCLC), sponsored by NTNU. Primary endpoint: Overall survival. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NL-OMON61474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61474.